SCHEMBL6900274

SCHEMBL6900274

O=P(O)(O)OC(F)(F)OP(=O)(O)O

nearest known ligand 0.39

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.39
FDPS P14324 1/20 0.39
BLM P54132 1/20 0.39
PGK1 P00558 2/20 0.36
PGK2 P07205 2/20 0.36
SMPD1 P17405 3/20 0.33
KDM4E B2RXH2 1/20 0.32
TSHR P16473 1/20 0.32
CA4 P22748 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1334769 0.83
SCHEMBL5491040 0.80 TDP1 (0.39) TDP1FDPSBLMPGK1PGK2
SCHEMBL2991822 0.80
SCHEMBL23062646 0.78 TDP1 (0.37) TDP1FDPSBLMPGK1PGK2
SCHEMBL2699115 0.78 TDP1 (0.37) TDP1FDPSBLMPGK1PGK2
SCHEMBL12694704 0.75
SCHEMBL2134670 0.75
Ethylene SCHEMBL29094194 0.75 TDP1 (0.35) TDP1FDPSBLMPGK1PGK2
SCHEMBL27592565 0.75 TDP1 (0.35) TDP1FDPSBLMPGK1PGK2
SCHEMBL588728 0.75 TDP1 (0.35) TDP1FDPSBLMPGK1PGK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103965242-A Synthesis method of novel difluoromethylene phosphate salt, and application of novel difluoromethylene phosphate salt SHANGHAI INST ORGANIC CHEM 2014-08-06 CN disclosed
CN-103965242-A Synthesis method of novel difluoromethylene phosphate salt, and application of novel difluoromethylene phosphate salt SHANGHAI INST ORGANIC CHEM 2014-08-06 CN disclosed
US-20040009123-A1 Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2004-01-15 US disclosed
US-20040006131-A1 Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2004-01-08 US disclosed
US-6624151-B1 Concerns the uses of said compounds as selective inhibitors of T gamma 9 delta 2 lymphocytes, their uses, for therapeutic purposes. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2003-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006131-A1 Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes CD4, IL2RA, CD74 TDP1 2384/4885FDPS 2429/4885BLM 4823/4885
US-20040009123-A1 Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes CD4, IL2RA, CD74 TDP1 2384/4885FDPS 2429/4885BLM 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.